指南与共识冠心病血脂与心血管预防

美国心脏协会科学声明:2型糖尿病合并稳定型冠心病的临床管理

Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association.
指南 / 共识 · Circulation · 2020-04-13

本声明由美国心脏协会发布,系统阐述2型糖尿病(T2DM)在稳定型冠心病(CAD)患者评估与治疗决策中的作用,强调T2DM影响检测选择、二级预防、稳定型心绞痛治疗及血运重建策略,并讨论血糖管理强度与药物选择对心血管结局的影响,呼吁心内科医生参与降糖药物选择。

要点

  • T2DM影响CAD检测选择、二级预防、稳定型心绞痛治疗及血运重建策略。
  • 血糖管理强度与降糖药物选择对心血管结局有实质影响。
  • 心内科医生需在心血管决策中考虑T2DM,并协助选择降糖药。

核心结论

  • 心内科医生应在CAD治疗决策中考虑T2DM,并可能协助指导降糖药物选择。

研究设计与样本

  • 美国心脏协会科学声明,基于现有证据总结T2DM合并稳定型CAD的以患者为中心的管理。

主要发现

  • T2DM不仅增加心血管风险,还影响CAD检测、二级预防、稳定型心绞痛治疗及血运重建策略的选择。
  • 血糖管理机制(控制强度与药物选择)对心血管结局有实质影响。

临床怎么用

  • 在CAD检测、二级预防、稳定型心绞痛治疗及血运重建策略选择中纳入T2DM因素。
  • 关注血糖管理强度与降糖药物选择对心血管结局的影响,并参与降糖药物决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients' cardiovascular outcomes.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Arnold SV, Bhatt DL, Barsness GW, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020. PMID: 32279539. doi:10.1161/CIR.0000000000000766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。